Related Experiment Video
Updated: Mar 19, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
[Insulinization in type 2 diabetes mellitus. Intensification options]
Graciela V Fuente1, Isaac Sinay2, José E Costa Gil3
1Unidad de Nutrición, Hospital Carlos Durand, Buenos Aires, Argentina.
Medicina
|June 14, 2016
Summary
Intensified insulin therapy helps prevent diabetes complications but can cause hypoglycemia and adherence issues. Insulin analogue combinations offer improved control and fewer side effects, enhancing treatment success.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Diabetes mellitus is linked to severe vascular complications, morbidity, and mortality.
- Effective insulin therapy is crucial for preventing or delaying diabetic complications.
- Hypoglycemia and poor treatment adherence are significant barriers to successful diabetes management.
Purpose of the Study:
- To evaluate the benefits of insulin analogue combinations in diabetes management.
- To explore solutions for improving metabolic control and patient adherence.
- To assess the impact of advanced insulin formulations on hypoglycemic events.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic properties of insulin analogues.
- Analysis of clinical benefits associated with insulin analogue combinations.
- Assessment of factors influencing treatment adherence in diabetes.
Main Results:
- Insulin analogue combinations demonstrate pharmacokinetic and pharmacodynamic advantages.
- These combinations lead to improved metabolic control in diabetic patients.
- A reduction in hypoglycemic events and enhanced treatment adherence are observed.
Conclusions:
- Insulin analogue combinations offer significant clinical benefits for diabetes mellitus.
- Simplicity of use with these combinations may improve patient adherence.
- Advanced insulin therapies are key to overcoming management challenges and improving patient outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
01:27Insulin Formulations: Types and Delivery
1.0K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.0K
01:22Diabetes Mellitus: Type 2 and Gestational
5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
891
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
891